Letermovir Wins FDA Approval -- Smallish But Steady Market Seen

Kenilworth will brand the drug as Prevymis^TM. It should reach $350 million in sales by 2020; we have been following its development and testing since mid-October of 2012.

From ABC News then -- a bit:

. . . .The Food and Drug Administration on Wednesday approved sales of Merck and Co.'s Prevymix (PREH'-vih-miss) to prevent infections with cytomegalovirus (sy-toe-MEG'-a-low-vy-rus), a common virus. It doesn't sicken most people, but strikes at least half of transplant patients, who are particularly vulnerable to infection. The virus can damage the eyes, lungs and other organs, trigger pneumonia and even kill.

Kenilworth, New Jersey-based Merck says the drug will cost $195 to $270 per day for 100 days. . . .

[Ahem. This is an automated post -- no human reviewed it. Errors appearing between these sheets (and I am sure there were/are some) here, will be corrected when the author is back on-line.]

नमस्ते